| Symbol | BRRGD |
|---|---|
| Name | ONCOINVENT ASA |
| Sector | UNDEFINED |
| Region | Europe |
| Industry | - |
| Address | 0484 Norway Gullhaugveien 7 |
| Telephone | +47 22 18 33 05 |
| Fax | — |
| — | |
| Website | https://www.oncoinvent.com/ |
| Incorporation | NO |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | — |
| Audit Status | AUDITED |
| Reporting Status | International Reporting: Oslo Bors |
| CIK | — |
| Description | Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body cavities, including peritoneum in two phase 1/2a trials and one randomized phase 2 trial. Additional info from OTC: |
No news found.